C1R and glioblastoma: For patients with highly invasive and treatment‐resistant mesenchymal subtype GBM, combining TEFT with TGF‐β/C1R targeted inhibitors may synergistically suppress mesenchymal transition, enhancing treatment sensitivity and efficacy.